Abstract
Most people in longevity medicine know Klotho for what it does to the aging clock — slowing it down, extending healthspan, protecting kidneys, sharpening cognition. But a rapidly growing body of research is revealing a second, equally compelling dimension to this protein: it is also one of the body’s most versatile tumor suppressors.
Across more than a dozen cancer types — from colorectal and breast to hepatocellular carcinoma, pancreatic ductal adenocarcinoma, and ovarian cancer — reduced Klotho expression consistently correlates with faster progression, greater invasiveness, drug resistance, and poorer survival. Conversely, restoring Klotho expression, even exogenously, slows tumor growth, resensitizes cells to chemotherapy, and triggers cancer-cell-selective apoptosis.
Understanding Klotho’s role in cancer is not only scientifically fascinating — it deepens the case for delivering this protein as part of a comprehensive biological rejuvenation strategy.
Why Aging and Cancer Share the Same Biological Language
At first glance, aging and cancer seem like opposites: one is a story of cellular decline, the other of uncontrolled cellular growth. Yet at the molecular level they are deeply intertwined — and Klotho sits at the convergence point.
Both processes are driven by the same underlying hallmarks: genomic instability, epigenetic dysregulation, chronic inflammation (inflammaging), cellular senescence, mitochondrial dysfunction, and gut microbiome disruption. Cancer incidence peaks alongside biological aging precisely because the cellular environment that promotes senescence also creates the conditions in which mutations accumulate and immune surveillance deteriorates.
Klotho acts as a buffer against both trajectories. It suppresses the very signaling cascades — TGF-β, Wnt/β-catenin, PI3K/Akt, IGF-1R — that, when dysregulated, accelerate both tissue aging and tumor formation. Declining Klotho levels with age therefore represent not just a loss of longevity signaling, but a gradual erosion of the body’s defenses against malignant transformation.
This duality is clinically significant. It means that strategies aimed at restoring Klotho — including gene therapy and the delivery of Klotho-rich exosomal cargo — may simultaneously address two of the most consequential processes in human biology.
α-Klotho: The Circulating Longevity Factor at the Center of Cancer Research
The Klotho most relevant to longevity medicine — and to cancer biology — is α-Klotho. Produced predominantly in the renal distal tubules, it is also detected in the brain (choroid plexus and neurons), skin, blood vessels, and peripheral blood cells. Its soluble form (sKL), generated through proteolytic shedding by ADAM-10 and ADAM-17 metalloproteases, circulates in plasma, urine, and cerebrospinal fluid and is considered the primary active form in systemic cancer suppression.
α-Klotho acts as a co-receptor for FGF23 in phosphate and mineral metabolism, but this represents only a fraction of its biological activity. Independently of FGF23, soluble α-Klotho engages a broad network of tumor-suppressive pathways — suppressing oncogenic signaling cascades, restoring apoptotic sensitivity, and remodeling the tumor microenvironment. Crucially, circulating sKL acts on tissues that do not themselves express Klotho, meaning its protective effects are systemic. This is why declining Klotho levels with age — well documented in both human and animal studies — translate into a gradual, body-wide erosion of tumor defenses.
Core Tumor-Suppressive Mechanisms
Klotho’s anti-cancer activity is not mediated by a single pathway but by simultaneous intervention at multiple points in the signaling networks that govern cell growth, survival, and invasion. Here are the key mechanisms documented in peer-reviewed research.
1. Inhibition of PI3K/Akt — The Master Growth Switch
The PI3K/Akt pathway is among the most frequently dysregulated axes in human cancer. Klotho suppresses it by blocking insulin and IGF-1 receptor autophosphorylation, reducing downstream tyrosine phosphorylation of IRS-1 and IRS-2, and preventing p85/PI3K association. The consequence: reduced cell proliferation, lower Akt-driven survival signaling, and restored sensitivity to apoptotic triggers. This mechanism has been demonstrated in colon, ovarian, lung, and renal cell carcinoma, making it arguably Klotho’s most broadly relevant anti-tumor action.
2. Wnt/β-Catenin Suppression — Blocking a Hallmark of Aging and Cancer
Wnt signaling is critical in embryogenesis and stem cell biology, but its hyperactivation is a driver of multiple cancers and a hallmark of accelerated tissue aging. Soluble Klotho directly binds Wnt ligands (Wnt1, Wnt3, Wnt4, Wnt5a), blocking their transcriptional activity and curbing the epithelial-mesenchymal transition (EMT) that makes cancer cells invasive. In hepatocellular carcinoma, overexpressing Klotho suppresses Wnt/β-catenin signaling and halts liver cancer cell proliferation. This same pathway drives the fibrosis and muscle stem cell dysfunction seen in aged tissue — reinforcing how Klotho’s tumor-suppressive and anti-aging functions are mechanistically inseparable.
3. TGF-β Pathway Inhibition — Dual Anti-Aging and Anti-Cancer Action
TGF-β is a central promoter of fibrosis, cellular senescence, and cancer metastasis. Klotho binds directly to the type II TGF-β receptor (TβRII), blocking TGF-β activity and curtailing downstream JNK, p38/MAPK, and NF-κB signaling. In the context of cancer, this reduces metastatic potential. In the context of aging, it reduces organ fibrosis — the same intervention operating across both disease landscapes.
4. Apoptosis Induction via TRAIL Death Receptors
One of the more striking findings in colorectal cancer research is that Klotho overexpression specifically sensitizes cancer cells — but not healthy colon cells — to apoptosis via the TRAIL receptor pathway. Activating the Klotho gene in Caco-2 colon cancer cells upregulated DR4 death receptors, inducing selective programmed cell death. This cancer-cell specificity is clinically relevant: it suggests Klotho-based interventions may carry a favorable safety profile.
5. Epigenetic Silencing — A Reversible Loss
A recurrent theme across gastric, pancreatic, ovarian, and hepatocellular cancers is that Klotho is not mutated in tumors — it is epigenetically silenced. Promoter hypermethylation, driven by DNMT enzymes upregulated in the tumor microenvironment, shuts off Klotho transcription without altering the gene itself. The therapeutic implication is significant: demethylating agents and microRNA inhibitors (e.g., miR-504 inhibition in PDAC) can restore Klotho expression and reverse the oncogenic phenotype. Exogenous Klotho delivery — as with soluble Klotho-carrying exosomes — bypasses this silencing entirely.
6. Chemotherapy Sensitization
In both lung and ovarian cancer models, Klotho overexpression substantially increased cancer cell sensitivity to cisplatin, one of the most widely used chemotherapy agents. In lung cancer specifically, the mechanism runs through PI3K/Akt inhibition: blocking this survival pathway with Klotho (or with LY294002) removed the pro-survival buffer that confers cisplatin resistance. For patients undergoing conventional treatment, higher Klotho levels — or exogenous supplementation — may improve therapeutic outcomes.
7. Suppression of the Senescent Stromal Microenvironment
One of the more nuanced findings involves the tumor microenvironment. Senescent stromal cells — fibroblasts and endothelial cells driven into senescence by chemotherapy or replicative exhaustion — secrete pro-inflammatory SASP factors including CCL2, which accelerates colorectal cancer cell invasion and proliferation. Exogenous Klotho inhibits NF-κB activation in these senescent stromal cells, preventing CCL2 transcription and dismantling this pro-tumor microenvironmental signal. In patient data, high CCL2 combined with low Klotho predicts significantly worse outcomes. This mechanism elegantly links inflammaging, cellular senescence, and cancer progression — and positions Klotho as an intervention that addresses all three simultaneously.
Klotho as Tumor Suppressor: An Evidence Summary
The table below summarizes the peer-reviewed evidence across the most extensively studied cancer types, drawing primarily from the 2025 systematic review by Ortega, Boaru et al. (Genes, 16:128) and associated primary literature.
| Cancer Type | Key Mechanism(s) | Clinical Relevance |
|---|---|---|
| Colorectal Cancer | Inhibits NF-κB; induces apoptosis via TRAIL receptors; blocks IGF1R/PI3K/Akt | Low KL = poor survival; reduced invasion when KL restored |
| Breast Cancer | Suppresses IGF-1 & insulin signaling; activates C/EBPβ tumor suppressor | Higher KL in normal vs. tumor tissue; KL1 domain reduces colony formation |
| Hepatocellular Carcinoma | Negatively regulates Wnt/β-catenin (α-KL); epigenetic silencing via promoter hypermethylation | KL promoter methylation = poor prognosis biomarker |
| Ovarian Cancer | Blocks IGF-1 pathway; reduces mesenchymal markers; enhances cisplatin sensitivity | Markedly reduced KL in high-grade tumors; wild-type BRCA association |
| Pancreatic Cancer (PDAC) | Inhibits tumor progression; sKL isoform suppresses xenograft growth | KL knockdown accelerates PDAC onset; DNA methylation = prognostic marker |
| Lung Cancer | Reduces cisplatin resistance via PI3K/Akt; suppresses EMT marker N-cadherin | KL overexpression = better chemotherapy response |
| Gastric Cancer | Epigenetically silenced via KL promoter hypermethylation; SOX17 restores KL | Demethylation restores KL; promoter status predicts prognosis |
| Renal Cell Carcinoma | Inhibits PI3K/Akt/GSK3β/Snail axis; suppresses EMT, migration & invasion | Lower KL in advanced RCC; inverse correlation with pAkt |
| Esophageal (ESCC) | Inversely correlated with β-catenin expression | KL-positive tumors = longer survival |
| Thyroid Cancer | Reduces proliferation; increases apoptosis; downregulates STC1 | High KL = low STC1; silencing KL enhances growth |
What This Means for Klotho Gene Therapy
The anti-cancer evidence for Klotho is not merely observational. Animal model and cell culture data show that exogenous delivery of Klotho protein — including the soluble sKL isoform delivered via viral vector in pancreatic cancer xenograft models — produces measurable tumor suppression. Importantly, this also demonstrates that restoring Klotho from outside the cell is sufficient to re-engage tumor-suppressive mechanisms, even in tissues where the gene has been epigenetically silenced.
This is precisely the rationale for Klotho gene therapy. Rather than delivering transient protein doses, gene therapy instructs the body’s own cells to produce soluble α-Klotho on an ongoing basis — restoring the circulating sKL levels characteristic of younger biological ages and maintaining the systemic tumor-suppressive environment over the long term. Sustained endogenous production is particularly relevant given the evidence that it is chronic Klotho deficiency, accumulating over years of aging, that progressively dismantles the body’s cancer defenses.
Clinical Perspective
BlastLongevity’s α-Klotho gene therapy is designed to restore circulating sKL levels to those observed in younger biological ages. Given the convergent evidence that declining Klotho is both a driver of aging and a permissive factor in tumor progression, this intervention addresses both trajectories simultaneously — and does so through sustained endogenous production rather than a short-lived protein dose.
It is important to note what the current evidence does and does not show. The research to date is largely preclinical — human clinical trials specifically targeting Klotho in cancer treatment are not yet complete. Klotho gene therapy at BlastLongevity is offered in the context of longevity and biological age reversal, not as a cancer treatment. Individuals with active malignancies should always work with their oncologist.
However, the convergence of mechanisms — from PI3K/Akt suppression to Wnt inhibition to chemotherapy sensitization — suggests that maintaining healthy Klotho levels across the lifespan represents a scientifically rational strategy for preserving the tumor-suppressive environment that declines with age.
Conclusion: One Protein, Two Battlegrounds
Klotho was discovered in 1997 as an anti-aging gene — a protein whose deficiency produced premature aging and whose overexpression extended lifespan. Nearly three decades of research have revealed that this longevity function and its emerging role in cancer suppression are not separate stories. They are the same story.
Aging dismantles tumor-suppressive environments. Declining Klotho is a central mechanism through which it does so. Restoring Klotho — through gene therapy, through the biological cargo of PSC-derived exosomes, through a comprehensive longevity program — is therefore an intervention that speaks simultaneously to healthspan, to organ resilience, and to the molecular conditions under which malignant transformation becomes either more or less likely.
Key References
- Ortega MA, Boaru DL, De Leon-Oliva D, et al. The Impact of Klotho in Cancer: From Development and Progression to Therapeutic Potential. Genes. 2025;16(2):128. doi:10.3390/genes16020128
- Ligumsky H, Merenbakh-Lamin K, Wolf I, Rubinek T. The Role of α-Klotho in Human Cancer: Molecular and Clinical Aspects. Oncogene. 2022;41:4487–4497.
- Liu Y, et al. Klotho-Mediated Targeting of CCL2 Suppresses the Induction of Colorectal Cancer Progression by Stromal Cell Senescent Microenvironments. Mol Oncol. 2019;13:2460–2475.
- Wolf I, et al. Klotho: A Tumor Suppressor and Modulator of the IGF-1 and FGF Pathways in Human Breast Cancer. Oncogene. 2008;27:7094–7105.
- Sun H, et al. Overexpression of Klotho Suppresses Liver Cancer Progression and Induces Cell Apoptosis by Negatively Regulating Wnt/β-Catenin Signaling Pathway. World J Surg Oncol. 2015;13:307.
- Wang Y, et al. Klotho Sensitizes Human Lung Cancer Cell Line to Cisplatin via PI3K/Akt Pathway. PLoS ONE. 2013;8:e57391.
- Rubinstein TA, et al. A Transgenic Model Reveals the Role of Klotho in Pancreatic Cancer Development and Paves the Way for New Klotho-Based Therapy. Cancers. 2021;13:6297.
- Zhu Y, et al. Klotho Suppresses Tumor Progression via Inhibiting PI3K/Akt/GSK3β/Snail Signaling in Renal Cell Carcinoma. Cancer Sci. 2013;104:663–671.
- Rubinek T, et al. Epigenetic Silencing of the Tumor Suppressor Klotho in Human Breast Cancer. Breast Cancer Res Treat. 2012;133:649–657.
- Lojkin I, et al. Reduced Expression and Growth Inhibitory Activity of the Aging Suppressor Klotho in Epithelial Ovarian Cancer. Cancer Lett. 2015;362:149–157.
